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A B S T R A C T
Epilepsy drug-resistance may depend on the metabolism of antiepileptic drugs (AEDs), transport to the
epileptic focus and/or target sensitivity. Furthermore, drug response depends onmultiple characteristics
of the patient, the epilepsy, and the antiepileptic drugs used.
We have investigated the association between polymorphisms related to antiepileptic drug
metabolism (CYP2C9, CYP2C19, and UGT), transport (ABCB1), and targets (SCN1A) both in a crude
analysis and after adjusting by clinical factors associated with drug-resistance, and stratifying by patient
age or aetiology of epilepsy.
Caucasian outpatients (N = 289), children (N = 80) and adolescent-adults (N = 209), with idiopathic
(N = 69), cryptogenic (N = 97) or symptomatic epilepsies (N = 123) were selected when they had either
drug-resistance (with at least four seizures over the previous year after treatment with more than three
appropriate AEDs at appropriate doses) or drug responsiveness (without seizures for at least a year).
Samples were genotyped by allelic discrimination using TaqMan probes.
No signiﬁcant association between polymorphisms and drug-resistancewas found either in the crude
analysis or in the adjusted analysis. However, adults with the ABCB1_3435TT or 2677TT genotypes had a
lower risk of drug-resistance than those with the CC or the GG genotypes. Furthermore, patients with
symptomatic epilepsies with the ABCB1_3435CT or TT genotypes had a lower risk of drug-resistance
than those with the CC genotype. An opposite but insigniﬁcant tendency was found in children and in
idiopathic epilepsies.
Although replication studies will be needed to conﬁrm our results, they suggest that stratiﬁcation by
patient age and by the aetiology of epilepsy could contribute to unmask the association between ABCB1
polymorphisms and drug-resistance of epilepsy.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a common, serious, and treatable neurological
disorder. Despite signiﬁcant advances in the therapy of epilepsy
over recent decades, about one third of patients with newly
diagnosed epilepsy will become refractory to treatment, with their
seizures impacting upon day-to-day activity, social well-being,
independence, economic output and quality of life.1–4
The mechanisms underlying the development of drug-resis-
tance in epilepsy are complex and, at this time, not fully* Corresponding author at: Servicio de Farmacologı´a Clı´nica, Hospital Universi-
tario Marque´s de Valdecilla, Avenida de Valdecilla s/n, E-39008 Santander, Spain.
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doi:10.1016/j.seizure.2009.12.004understood.5 Drug-resistance depends on a number of clinical
aspects including aetiology, early age at seizure onset, type of
epileptic syndrome and seizure, structural brain abnormalities or
lesions, or abnormal electroencephalographic ﬁndings.1–4 Further-
more, drug-resistance may depend on genetic and acquired factors
affecting pharmacokinetics or pharmacodynamics of AEDs. Genet-
ic factors may reduce serum drug concentrations either by
reducing absorption or by increasing elimination and/or the access
of AEDs to the epileptic focus in the central nervous system (CNS).
In addition, genetic factors may be responsible of changes in AED
targets reducing the response to drugs.3,6,7
Many AEDs are metabolised by the cytochrome P450 (CYP) and
uridin diphosphate glucuronosyl transferase (UGT) superfamilies.
CYP2C9 contributes to the metabolism of phenytoin and valproic
acid; CYP2C19 contributes to the metabolism of phenytoin,
diazepam and phenobarbital.7–10 Two polymorphisms of CYP2C9vier Ltd. All rights reserved.
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to a degree that increases the risk of the neurotoxic effects of this
drug among carriers of these polymorphisms, whereas the
inﬂuence of CYP2C19 polymorphisms is minor.7,10,11 The UGT
isozymes evolved in themetabolism of each anticonvulsant are not
yet well deﬁned and some anticonvulsants can be metabolised by
more than one isozyme. UGT1A1may be implicated in lamotrigine
metabolism.12 UGT2B7 contributes to valproic acid,13,14 carba-
mazepine,15 lamotrigine16 and lorazepam glcuronidation.9,14
UGT2B15 participates in lorazepam metabolism.17 However, the
functional signiﬁcance of UGT2B7 polymorphisms is unclear.18 In
one study, AUCs of valproate increased with the number of
UGT2B7*2 alleles, but the difference was insigniﬁcant.14
Drug-resistance may also be caused because sufﬁcient intra-
parenchymal AED concentrations are not attained in the epileptic
focus by an enhanced function of multidrug transporters or
because target sites are structurally and/or functionally modiﬁed
and become less responsive to AEDs.5,19,20
In 2003, Siddiqui et al. reported the 3435C>T polymorphism in
the ABCB1 gene as being associated with resistance to multiple
AEDs. Patients with multidrug-resistant epilepsy were signiﬁcant-
ly more likely to have CC than TT genotype.21 Because the CC
genotype has been associated with increased expression of
intestinal P-glycoprotein,22 the data of Siddiqui et al.21 suggested
that CC genotypemay be associatedwith increased expression and
functionality of P-glycoprotein also at the blood–brain barrier,
leading to reduced AED concentrations at their brain targets.
Several studies have conﬁrmed the association of ABCB1_3435C>T
or ABCB1_2677G>T polymorphisms with drug-resistance, but
other studies could not ﬁnd it.7 In a recent meta-analysis, an
association between ABCB1 polymorphisms and antiepileptic
drugs response was not found.23 Differences in methodology
and patients’ recruitment from one study to anothermay inﬂuence
the results.7 Most studies were performed in multiple types of
epilepsy and with multiple AEDs, but no attempt was made to
separate children from adults or idiopathic from cryptogenic and
symptomatic epilepsies despite there being important differences
in drug-resistance and type of antiepileptic drugs used in each
subgroup.
With respect to AED targets, the inhibition of voltage-gated
sodium channels is the main mechanism of most AEDs, and
mutations in SCN1A gene have been associated with different
types of genetic epilepsies.6 Furthermore, SCN1A_IVS5N+5G>A
polymorphism has been associated with the maximum tolerated
dose of phenytoin and carbamazepine.24,25
The primary goals of this study were the following: (i) to
analyze the association between several single nucleotide poly-
morphisms (SNPs) of the CYP2C9, CYP2C19, UGT2B7, ABCB1, and
SCN1A genes by bivariate analysis and (ii) to analyze these
associations taking into account some factors related with the
patient and his/her epilepsy by multivariate analysis. The
secondary goal was to investigate these associations stratifying
patients by patient age and epilepsy aetiology.
2. Materials and methods
The protocol for this observational study was approved by the
Regional Ethics Committee and it was carried out in accordance
with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans.26
Written informed consent was obtained from patients or from
their parents or legal guardians.
The study was carried out on 289 outpatients attending the
Neuropediatrics and Neurology Services at the Marque´s de
Valdecilla University Hospital. These Services are the neurological
reference Services attending most epileptic patients in Cantabria,an autonomous community at the north of Spain with about
600,000 inhabitants.
Patients, all Caucasians, were included when they had an
established clinical diagnosis of epilepsy (deﬁned by the occur-
rence of two or more unprovoked seizures) conﬁrmed by an
electroencephalogram examination by an expert. Furthermore,
patients were included when they had either drug-resistant or
drug-responsive epilepsy according to the following deﬁnitions
and criteria. Drug-resistance was deﬁned as the occurrence of at
least four seizures over the year before recruitment with trials of
more than three appropriate AEDs at maximal tolerated doses,
which were established on the basis of the occurrence of clinical
side effects at supra-maximal doses or trough serum concentra-
tions at the higher limit of the optimal interval. Only the
recognized, more speciﬁc drugs for a syndrome were considered
appropriate. Drug responsiveness was deﬁned as complete
freedom from seizures for at least a year, up to the date of the
last follow-up visit, in patients with epilepsy treated with AEDs.
Medical history of each patient was revised by the two
neuropediatricians and the two neurologists participating in the
study. Data collected before genotyping on a speciﬁc formwere the
following: patient age and gender, family history of epilepsy (yes/
no) and/or febrile seizures (yes/no), past medical history of
troubles during pregnancy, labour or post-labour (6 categories),
electroencephalographic location of paroxysmal activity (14
categories), age at the onset of epilepsy, type of seizures
(generalized or partial), aetiology of the epilepsy (idiopathic,
cryptogenic or symptomatic), and presence of neurological
alterations (yes/no). Symptomatic epilepsies were dues to the
following causes according to the classiﬁcation of Engel27:
neurocutaneous disorders (N = 8), malformations due to abnormal
cortical developments (N = 13), other cerebral malformations
(n = 16), tumours (N = 3), chromosomal abnormalities (N = 1),
inherited metabolic disorders (N = 3), prenatal or perinatal
ischemic or anoxic lesions or cerebral infections causing nonpro-
gressive encephalopathies (N = 36), postnatal infections (N = 6),
other postnatal factors (N = 37). Previous and actual treatments
(AEDs, dosages and trough steady-state serum concentrations)
were also collected.
Blood samples for genotyping (5 mL) were obtained with EDTA
through the venopunction used for pharmacokinetic monitoring
and frozen at 80 8C for 24 h. DNA was extracted from 200 mL of
blood (Puregene1 DNA puriﬁcation kit of Gentra Systems, 10th
Avenue North, Minneapolis, MN, USA) according to the manu-
facturer’s instructions. Between 3 and 10 mg of DNAwere obtained
from 200 mL of blood.
SNPs genotyped and Applied Biosystems Taqman Drug
Metabolism Genotyping Assays used are displayed in Table 1.
Predeveloped Taqman assay reagents for allelic discrimination
were used for all SNPs except the one for ABCB1_2677G>T, which
was developed in our laboratory. Fifty nanograms of DNA were
used and the manufacturer’s instructions were followed. Polymer-
ase chain reaction ampliﬁcation consisted of an initial denatur-
ation for 5 min at 95 8C, followed by 50 cycles of denaturation at
92 8C for 1 min, annealing at 57 8C for 50 s and an extension at
72 8C for 1 min. PCR reactions were carried out in a Bio-Rad iCycler
thermocycler (Bio-Rad, Hercules, California, USA). Samples
remained at 4 8C until visualization. Visualization of ﬂuorescence
in each sample at the end of the reaction was performed by the
Stratagene MX3000P QPCR System (Agilent Technologies Compa-
ny, La Jolla, CA, USA), using the MxProQPCR software. Genotyping
was performed in a blinded fashion with respect to the drug-
resistance condition of the patient. ABCB1_2677G>T genotypes
were conﬁrmed by an alternative method using the polymerase
chain reaction-restriction fragment length polymorphism method
described by Cascorbi et al.28
Table 1
Polymorphisms genotyped.
Gene Mutant allele Aminoacid change
and position
Location NCBI reference Applied Biosystems
Assay ID
CYP2C9 CYP2C9*2, c.430C>T Cys/Arg [144] Chr.10/exn 3 rs1799853 C_25625805_10
CYP2C9 CYP2C9*3, c.1075A>C Leu/Ile [359] Chr.10/exon 7 rs1057910 C_27104892_10
CYP2C19 CYP2C19*2, c.681G>A Pro/Pro [227] Chr.10/exon 5 rs4244285 C_25986767_70
CYP2C19 CYP2C19*3, c.636 G>A Ter*/Trp [212] Chr.10/exon 4 rs4986893 C_27861809_10
UGT1A1 UGT1A1*27, c.686C>A Pro/Gln [229] Chr.2/exon 1 rs35350960 C_2307598_20
UGT2B7 UGT2B7, c.372A>G Arg/Arg [124] Chr.4/exon 1 rs28365063 C_30689135_20
UGT2B7 UGT2B7, c.-161C>T His/Tyr [268] Chr.4/promoter region rs7668258 C_27827970_40
ABCB1 ABCB1, c.3435 C>T Ile/Ile [1145] Chr.7/exon 26 rs1045642 C_7586657_20
ABCB1 ABCB1, c.2677 G>T Ala/Ser [893] Chr.7/exon 21 rs2032582 –
SCN1A SCN1A, c.3166 A>G Thr/Ala [1056] Chr.2/exon 16 rs2298771 C_11748767_20
SCN1A SCN1A, IVS5N+5 G>A – Chr.2/intron 4 rs3812718 C_25982233_10
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into children (12 years) and adolescent-adults (>12 years)
subgroups. To evaluate the inﬂuence of the aetiology of epilepsy,
patients were divided into idiopathic, cryptogenic and symptom-
atic epilepsy subgroups. The statistical analysis was carried out
using the SPSS for Windows version 15.0 software (SPSS Inc.,
Chicago, IL, USA) and the SNPStats software.29 SPSS was used to
compare genotypic frequencies between drug-responsive and
drug-resistant patients, and to analyze the association between
each polymorphism and drug-resistance by binary logistic
regression between both in a bivariate analysis without including
clinical factors, and in a multivariate analysis taking into account
clinical factors. SNPStats was used to compare observed and
expected frequencies bymeans of the Hardy–Weinberg test, and to
analyze the interaction between each polymorphism and covari-
ates. A two-sided test (P < 0.05) was considered signiﬁcant
throughout.
3. Results
Characteristics of drug-sensitive and drug-resistant patients are
shown in Table 2. Signiﬁcant differences between drug-responsive
and drug-resistant patients were found in past medical history
(P = 0.016), type of seizure (P < 0.001), age at the onset of epilepsy
(P < 0.001), aetiology of epilepsy (P < 0 .001), and neurological
alterations (P < 0.001).
Hardy–Weinberg equilibrium was observed for all the poly-
morphisms studied except for ABCB1_2677G>T (P = 0.007). No
signiﬁcant association between drug-resistance and each poly-
morphism was observed either in the bivariate analysis (without
including clinical factors) or the multivariate analysis in which
clinical factors were taken into account by means of logistic
regression (Table 3).
However, signiﬁcant associations between ABCB1 polymorph-
isms and drug-resistancewere foundwhen patientswere stratiﬁed
by patient age or aetiology of epilepsy. When patients were
stratiﬁed by patient age, a signiﬁcant association was observed
between ABCB1_3435C>T and ABCB1_2677G>T polymorphisms
and drug-resistance in adults, but not in children. In adults,
frequencies of ABCB1_3435TT and ABCB1_2677TT genotypes were
signiﬁcantly lower than those of ABCB1_3435CC or
ABCB1_2677GG genotypes (P = 0.019 and P = 0.03, respectively).
The crude odds ratios indicated a lower risk of drug-resistance in
the patients with the genotype TT than in those with the genotype
CC (OR: 0.40, 95%CI: 0.19–0.86) or GG (OR: 0.41, 95%CI: 0.18–0.92).
In children, an opposite tendency was observed, suggesting a
higher risk in patients with genotypes TT than CC or GG, but
statistical signiﬁcance was not achieved (Table 4). The interaction
between the patient age factor and ABCB1 polymorphisms was
signiﬁcant both for ABCB1_3435C>T (P = 0.033) and for
ABCB1_2677G>T (P = 0.021).With respect to the aetiology of epilepsy, a signiﬁcant
association between ABCB1_3435C>T polymorphism and drug-
resistance was to be found in the subgroup of patients with
symptomatic epilepsy (P = 0.011) but not in those with idiopathic
or cryptogenic epilepsies. In the subgroup of patients with
symptomatic epilepsy, frequency of ABCB1_3435TT genotype
was signiﬁcantly lower than that of CC genotype in drug-resistant
patients (P = 0.003). The crude odds ratio indicated a lower risk of
drug-resistance in the patients with the genotype CT or TT than in
those with the genotype CC (OR: 0.39, 95%CI: 0.16–0.94 and OR:
0.20, 95%CI: 0.07–0.58, respectively). In contrast, a tendency to a
higher risk in patients with genotypes CT or TT than CC was
observed in patients with idiopathic epilepsies, but differences
were not statistically signiﬁcant (Table 5). The interaction between
the epilepsy aetiology factor and the ABCB1_3435C>T polymor-
phism was signiﬁcant (P = 0.005).
4. Discussion
Mechanisms of epilepsy drug-resistance are complex and
multifactorial and, therefore, it may be difﬁcult to ﬁnd a signiﬁcant
associationwith a SNP. In fact, when all patientswere analyzed as a
whole, signiﬁcant associations between the SNPs included in our
study and epilepsy drug-resistance were not found in the bivariate
analysis in which demographic and clinical factors were not
considered.
Our hypothesis was that the association of polymorphismswith
drug-resistance could be masked by the unequal presence of
factors known to inﬂuence drug-resistance of epilepsy. Therefore,
we consider necessary to analyze the association between
polymorphisms and drug-resistance taking into account and
stratifying patients by clinical factors that inﬂuence drug-
resistance of epilepsy. In fact, in our study there was a signiﬁcant
association of drug-resistancewith covariates such as past medical
history, type of seizures, age at the onset of epilepsy, aetiology of
epilepsy or neurological alterations. However, when the associa-
tion between polymorphisms and drug-resistance was adjusted by
clinical factors by means of logistic regression, a signiﬁcant
association between the SNPs studied and drug-resistance was
neither found.
Studies investigating the association between polymorphisms
and drug-resistance adjusting by clinical factors are scarce. In the
study of Seo et al.30 in Japanese patients, in which the risk of drug-
resistance was higher in patients of low age at the onset of
epilepsy, in those with generalized seizures, and in those with
cryptogenic and symptomatic epilepsies, a signiﬁcant but opposite
association was found because ABCB1_3435TT frequency was
higher in drug-resistant patients. In contrast, in another study
in Chinese patients, a signiﬁcant association between
ABCB1_3435C>T and ABCB1_2677G>T polymorphisms and
drug-resistance was found when the odds ratio was adjusted by
Table 2
Characteristics of drug-responsive and drug-resistant patients.
Covariate Categories Drug-responsive
patients (N=178)
Drug-resistant
patients (N=111)
Binary logistic regression
(bivariate analysis)
Frequency % Frequency % OR (95%CI) P
Patient age in years (M SD) 26.019.8 27.018.5 1.00 (0.99–1.02) NS
Patient age groups 12 years 52 29.2 28 25.2 1.00
>12 years 126 70.8 83 74.8 1.22 (0.72–2.09) NS
Gender Males 88 49.4 56 50.5 1.00
Females 90 50.6 55 49.5 0.96 (0.60–1.54) NS
Family history of epilepsy No 154 86.5 104 93.7 1.00
Yes 24 13.5 7 6.3 0.43 (0.18–1.04) NS
Family history of febrile seizures No 172 96.6 105 94.6 1.00
Yes 6 3.4 6 5.4 1.64 (0.52–5.21) NS
Past medical history No 125 70.2 62 55.9 1.00 NS
In pregnancy 4 2.2 1 .9 0.50 (0.06–4.61) NS
In labour 10 5.6 10 9.0 2.02 (0.80–5.10) NS
Neonatal 4 2.2 2 1.8 1.01 (0.18–5.66) NS
Postnatal 30 16.9 26 23.4 1.75 (0.95–3.21) NS
More than one 5 2.8 10 9.0 4.03 (1.32–12.31) 0.014
Past medical history No 125 70.2 62 55.9 1.00
Yes 53 29.8 49 44.1 1.86 (1.14–3.05) 0.013
EEG location of paroxysmal activity Without a deﬁned focus 22 12.4 9 8.1 1.00 NS
Centrotemporal 9 5.1 4 3.6 1.09 (0.27–4.45) NS
Temporal 41 23.0 22 19.8 1.31 (0.52–3.33) NS
Frontal 6 3.4 6 5.4 2.44 (0.62–9.64) NS
Parietal 7 3.9 3 2.7 1.05 (0.22–5.00) NS
Occipital 5 2.8 3 2.7 1.47 (0.29–7.47) NS
Multifocal 8 4.5 8 7.2 2.44 (0.70–8.53) NS
Generalized 44 24.7 27 24.3 1.50 (0.60–3.73) NS
Fronto-parieto-occipital 2 1.1 1 .9 1.22 (0.10–15.23) NS
Temporo-parietal 3 1.7 2 1.8 1.63 (0.23–11.46) NS
Temporo-parieto-occipital 9 5.1 1 .9 0.27 (0.03–2.47) NS
Fronto-temporal 17 9.6 18 16.2 2.59 (0.93–7.18) NS
Fronto-parietal 0 0 3 2.7 – NS
Temporo-occipital 2 1.1 1 .9 1.22 (0.10–15.23) NS
Type of seizure Simple partial 6 3.4 3 2.7 1.00 <0.001
Complex partial 13 7.3 8 7.2 1.23 (0.24–6.36) NS
Secondarily generalized 67 37.6 24 21.6 0.72 (0.17–3.19) NS
Absence 12 6.7 2 1.8 0.33 (0.04–2.56) NS
Myoclonic 5 2.8 6 5.4 2.40 (0.39–14.88) NS
Tonic 2 1.1 6 5.4 6.00 (0.72–49.84) NS
Tonic-clonic 28 15.7 1 .9 0.07 (0.01–0,81) 0.033
Spasm 0 0 2 1.8 – NS
Several types 43 24.2 59 53.2 2.74 (0.65–11.59) NS
Age at the onset of epilepsy in years M SD 16.617.5 8.911.7 0.96 (0.94–0.98) <0.001
Type of epilepsy Generalized 52 29.2 27 24.3 1.00
Partial 126 70.8 84 75.7 1.28 (0.75–2.21) NS
Aetiology of epilepsy Idiopathic 60 33.7 9 8.1 1.00 <0.001
Cryptogenic 60 33.7 37 33.3 4.11 (1.83–9.26) 0.001
Symptomatic 58 32.6 65 58.6 7.47 (3.41–16.38) <0.001
Type of epilepsy-syndrome Idiopathic generalized 50 28.1 7 6.3 1.00 <0.001
Epileptic encephalopathy 3 1.7 21 18.9 50.0 (11.78–212.17) <0.001
Idiopathic partial 10 5.6 1 .9 0.71 (0.08–6.46) NS
Cryptogenic partial 60 33.7 34 30.6 4.05 (1.65–9.92) 0.002
Symptomatic partial 55 30.9 48 43.2 6.23 (2.58–15.04) <0.001
Neurological alterations No 131 73.6 56 50.5 1.00
Yes 47 26.4 55 49.5 2.74 (1.66–4.51) <0.001
Number of treatments 1 98 55.1 0 0
2 33 18.5 1 .9
3 20 11.2 22 19.8
4 14 7.9 18 16.2
5 10 5.6 15 13.5
6–10 3 7.1 41 36.9
>10 0 0 14 2.6
P: signiﬁcance of Wald statistic.
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Table 3
Association between each polymorphism and drug-resistance crude and adjusted by clinic covariates.
Polymorphism Genotype Drug-resistant patients Crude odds ratio Adjusted odds ratio
No (N=178)
Frequency (%)
Yes (N=111)
Frequency (%)
OR (95%CI) P OR (95%CI) P0
CYP2C9*2 *1/*1 134 (75.3) 88 (79.3) 1.00 NS 1.00 NS
*1/*2 39 (21.9) 21 (18.9) 0.82 (0.45–1.49) NS 0.56 (0.24–1.30) NS
*2/*2 5 (2.8) 2 (1.8) 0.61 (0.12–3.21) NS 0.33 (0.05–2.40) NS
CYP2C9*3 *1/*1 148 (83.1) 89 (80.2) 1.00 – 1.00 –
*1/*3 30 (16.9) 22 (19.8) 1.22 (0.66–2.24) NS 1.23 (0.53–2.88) NS
CYP2C19*2 *1/*1 123 (69.1) 85 (76.6) 1.00 NS 1.00 NS
*1/*2 47 (26.4) 24 (21.6) 0.74 (0.42–1.30) NS 0.62 (0.28–1.34) NS
*2/*2 8 (4.5) 2 (1.8) 0.36 (0.08–1.75) NS 0.39 (0.05–2.84) NS
CYP2C19*3 *1/*1 175 (98.3) 111 (100.0) 1.00 – 1.00 –
*1/*3 3 (1.7) 0 – NS – NS
UGT2B7_372A>G AA 107 (60.1) 66 (59.5) 1.00 NS 1.00 NS
AG 67 (37.6) 39 (35.1) 0.94 (0.57–1.56) NS 0.80 (0.41–1.58) NS
GG 4 (2.2) 6 (5.4) 2.43 (0.66–8.94) NS 2.80 (0.42–18.76) NS
UGT2B7_-161C>T CC 48 (27.0) 29 (26.1) 1.00 NS 1.00 NS
CT 94 (52.8) 57 (51.4) 1.00 (0.57–1.77) NS 0.69 (0.33–1–46) NS
TT 36 (20.2) 25 (22.5) 1.15 (0.58–2.29) NS 1.00 (0.41–2.45) NS
ABCB1_34435C>T CC 52 (29.2) 40 (36.0) 1.00 NS 1.00 NS
CT 81 (45.5) 49 (44.1) 0.79 (0.46–1.36) NS 0.65 (0.30–1.40) NS
TT 45 (25.3) 22 (19.8) 0.64 (0.33–1.22) NS 0.53 (0.21–1.32) NS
ABCB1_2677G>T GG 66 (37.1) 48 (43.2) 1.00 NS 1.00 NS
GT 74 (41.6) 43 (38.7) 0.80 (0.47–1.36) NS 0.64 (0.31–1.34) NS
TT 38 (21.3) 20 (18.0) 0.72 (0.38–1.40) NS 0.63 (0.25–1.58) NS
SCN1A_3166A>G GG 19 (10.7) 14 (12.6) 1.00 NS 1.00 NS
GA 88 (49.4) 54 (48.6) 0.83 (0.39–1.80) NS 1.40 (0.48–4.09) NS
AA 71 (39.9) 43 (38.7) 0.82 (0.37–1.81) NS 1.14 (0.37–3.53) NS
SCN1A_IVS5N+5G>A CC 41 (23.0) 26 (23.4) 1.00 NS 1.00 NS
CT 84 (47.2) 58 (52.3) 1.09 (0.60–1.97) NS 1.45 (0.64–3.27) NS
TT 53 (29.8) 27 (24.3) 0.80 (0.41–1.58) NS 0.76 (0.28–2.05) NS
P: signiﬁcance of Wald statistic and odds ratio by logistic regression (bivariate analysis). P0: signiﬁcance of Wald statistic and odds ratio by logistic regression including as
factors patient age groups, gender, family history of epilepsy, family history of febrile seizures, past medical history, EEG location of paroxysmal activity, type of seizures, type
of epilepsy, aetiology of epilepsy, and presence of neurological alterations, and as covariate the age at the onset of epilepsy.
M.B. Sa´nchez et al. / Seizure 19 (2010) 93–101 97the presence of mesial temporal lobe epilepsy.31 In a recent study,
the intronic polymorphism rs3789243 and the coding polymor-
phism 2677G/T/A, and haplotypes containing them, were associ-
ated with drug-resistance, and the 2677G/T/A genotypes remained
signiﬁcantly associatedwith drug-resistance aftermultiple logisticTable 4
Genotypic frequencies and drug-resistance odds ratios for each genotype in children a
Subgroups of age Genotype Drug-responsive patients
N (%)
A. ABCB1_3435C>T
Children (N=80) CC 15 (28.8)
CT 28 (53.8)
TT 9 (17.3)
Adults (N=209) CC 37 (29.4)
CT 53 (42.1)
TT 36 (28.6)
Test for interaction in the trend
B. ABCB1_2677G>T
Children (N=80) GG 20 (38.5)
GT 25 (48.1)
TT 7 (13.5)
Adults (N=209 GG 46 (36.5)
GT 49 (38.9)
TT 31 (24.6)
Test for interaction in the trend
P: signiﬁcance of Wald statistic and odds ratio were obtained by binary logistic regres
analysis).regression and correction for multiple comparisons.32 Whether
differences in results between studies depend on methodological
aspects, chance or ethnic factors remains to be clariﬁed.
With respect to the other SNPs included in our study, we have
not found any study investigating their association with epilepsynd adults for ABCB1_3435C>T and ABCB1_2677G>T polymorphisms.
Drug-resistant patients Crude odds ratio (95%CI) P
N (%)
4 (14.3) 1.00 NS
16 (57.1) 2.14 (0.62–7.57) NS
8 (28.6) 3.33 (0.78–14.31) NS
36 (43.4) 1.00 NS
33 (39.8) 0.64 (0.34–1.20) NS
14 (16.9) 0.40 (0.19–0.86) 0.019
0.033
8 (28.6) 1.00 NS
11 (39.3) 1.10 (0.37–3.25) NS
9 (32.1) 3.21 (0.89–11.60) NS
40 (48.2) 1.00 NS
32 (38.5) 0.75 (0.41–1.39) NS
11 (13.2) 0.41 (0.18–0.92) 0.030
0.021
sion between ABCB1_3435C>T or ABCB1_2677G>T and drug-resistance (bivariate
Table 5
Genotypic frequencies, signiﬁcance of the association between ABCB1_3435C>T polymorphism and drug-resistance and odds ratios in patients suffering from idiopathic,
cryptogenic or symptomatic epilepsies.
Aetiology of epilepsy Genotype Drug-responsive
patients
Drug-resistant
patients
OR (95%CI) P
N N
Idiopathic (N=69) CC 22 (36.7) 1 (11.1) 1.00 NS
CT 27 (45.0) 4 (44.4) 3.26 (0.34–31.30) NS
TT 11 (18.3) 4 (44.4) 8.00 (0.80–80.40) NS
Cryptogenic (N=97) CC 20 (33.3) 13 (35.1) 1.00 NS
CT 25 (41.7) 16 (43.2) 0.98 (0.39–2.52) NS
TT 15 (25.0) 8 (21.6) 0.82 (0.27–2.48) NS
Symptomatic (N=123) CC 10 (17.2) 26 (40.0) 1.00 0.011
CT 29 (50.0) 29 (44.6) 0.39 (0.16–0.94) 0.036
TT 19 (32.8) 10 (15.4) 0.20 (0.07–0.58) 0.003
Test for interaction in the trend: 0.005
P: signiﬁcance of Wald statistic and odds ratio were obtained by binary logistic regression between ABCB1_3435C>T and drug-resistance (bivariate analysis).
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after excluding patients with febrile convulsions, heterozygous
CYP2C8*4 and CYP2C9*3 were underrepresented among non-
responder patients with epilepsy.33
The lack of association between the SNPs included in our study
and drug-resistance may be attributed to several factors. Firstly,
the sample of our study may be not large enough, and therefore,
the power of the study may be insufﬁcient to detect a signiﬁcant
association. Perhaps, it could be demonstrated in a larger study.
Secondly, some polymorphisms such as those relatedwith CYP2C9,
CYP2C19 and UGT2B7 are associated with the metabolism of some
speciﬁc AEDs but not with others. Our study was not designed to
analyze the association between polymorphisms and drug-
resistance in patients treated with a speciﬁc AED. The association
between CYP2C9, CYP2C19 and drug-resistance should better be
studied in patients treated with phenytoin, valproate or pheno-
barbital, and the association with UGT2B7 in patients treated with
valproate or lamotrigine. Thirdly, polymorphisms affecting AED
metabolism are expected to exert an inﬂuence on serum
concentrations of AEDs and to produce insufﬁcient concentrations,
but in our study serum concentrations of AEDs were monitorized
and maintained into the optimal range.
However, when patients were stratiﬁed by patient age or
aetiology of epilepsy a signiﬁcant association between ABCB1 SNPs
studied and drug-resistance was found in some subgroups. With
regard to patient age, a lower risk of drug-resistance was observed
in patients with the 3435TT or 2677TT genotypes than in those
with the 3435CC or the 2677GG genotypes in adults but not in
children. With regard to epilepsy aetiology, the risk of drug-
resistance was lower in patients with the 3435CT or TT genotypes
than in those with the CC genotype in patients with symptomatic
epilepsies but not in those with idiopathic or cryptogenic
epilepsies. These results have a biological plausibility. First,
because several AEDs frequently used in the treatment of
epilepsies are substrates of P-glycoprotein both in rodents
(gabapentin, lamotrigine, phenobarbital, phenytoin, and topira-
mate) and humans (phenytoin, phenobarbital, lamotrigina, and
levetiracetam).34,35 Data on carbamazepine and levetiracetam are
not clear and valproic acid does not seem to be a substrate of P-
glycoprotein.35–38
Second, because some of these AEDs such as phenytoin and
phenobarbital are more frequently used in adults than in children
andinsymptomaticepilepsies than in idiopathicepilepsies,whereas
valproate is more frequently used in children and in idiopathic
epilepsies. Furthermore, because some antiepileptic drugs are
inhibitors of P-glycoprotein (in decreasing order phenytoin> carbamazepine> lamotrigine> phenobarbital > valproic acid,
levetiracetam, gabapentin) and because the ABCB1 polymorphisms
inﬂuence on this inhibitory effect, the intracellular concentration of
theP-glycoprotein substrateswill dependonABCB1polymorphisms
and on the combination of antiepileptic drugs (substrates and
inhibitors) used.
Third, because P-glycoprotein is overexpressed in patients with
symptomatic epilepsies such as tumours, dysplasias and hippo-
campal sclerosis.39 Although the inﬂuence of ABCB1 polymorph-
isms on brain expression of P-glycoprotein is controversial because
of the described lack of inﬂuence on ABCB1 mRNA and protein
expression,40,41 it has been suggested that an important reduction
in the access of AEDs to the CNS could be observed in patients over-
expressing this protein by the combined effect of genetic factors
and the own symptomatic epilepsy.7
The association of ABCB1_3435C>T polymorphism with drug-
resistance of epilepsy has been the most studied one, but there is
disagreement in the results.7After the initial studyofSiddiqui et al.21
in which an increased prevalence of the ABCB1_3435CC genotype
was reported in patients with drug-resistant epilepsy, several
studies in patients from different ethnicities have conﬁrmed an
association of both ABCB1_3435C>T SNP and the common
ABCB1_3435C>T, ABCB1_2677G>T, and ABCB1_1236C>T haplo-
typewith drug-resistance.31,42–45 In contrast, in two studies in non-
Caucasian patients, there was found to be the opposite association
with a higher frequency of TT genotypes in patients with drug-
resistant epilepsy than in those with drug-responsive epilepsy.30,46
Other studies in either Caucasians and non-Caucasians patients
were not able to demonstrate an association between ABCB1
polymorphisms and drug-resistance.33,47–57
Differences in results between studies have been attributed to
phenotype deﬁnition (i.e., deﬁnition of resistance versus response
to AEDs, inadequate power, potential confounding by comorbidity
and comedication, population substructure, genotyping error,
overlap in substrate speciﬁcity between P-glycoprotein and other
drug efﬂux transporters, and inclusion of AEDs thatmight not be P-
glycoprotein substrates).7,51
Most of these studies have been performed in patients treated
with multiple AEDs. However, in studies performed with one AED,
an association between ABCB1_3435C>T polymorphism and drug-
resistance was found in patients treated with phenytoin45 or
phenobarbital,58 whereas in those with carbamazepine an oppo-
site association30 or non-association52 was found.
Regarding patient age, children are more frequently treated
with valproate and carbamazepine, whereas adults are more
frequently treated with phenytoin or phenobarbital. Therefore, an
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might be better expected in adults than in children. In a recent
study, the association between ABCB1, ABCC2, CYP2C8, CYP2C9,
and CYP2C19 polymorphisms and drug-resistance of epilepsy was
studied in Caucasian children-adolescent, either drug-sensitive or
drug-resistant, and in drug-resistant adults.33 These investigators
found that carriers of the putatively low-expression ABCC2-24T
variant were signiﬁcantly overrepresented among non-responders
children-adolescent. This surprising associationwas attributed to a
compensatory up-regulation of ABCB1.33 In other recent study, in
south Indian patients, a signiﬁcant association between
ABCB1_1236C>T, ABCB1_2677G>A and ABCB1_3435C>T poly-
morphisms and drug-resistance of epilepsy in children-adolescent
were not found, but the frequency of ABCB1_3435TT genotypewas
higher in drug-resistant than in drug-sensitive patients.57 None of
these studies compared the association between ABCB1 poly-
morphisms and drug-resistance in children under 12 years with
that of adolescent-adults.
On the other hand, most of these studies were performed in
patients with different types of epilepsy.7 Our results show a
signiﬁcant association between ABCB1_3435C>T polymorphism
and drug-resistance in patients with symptomatic epilepsy that
was not found in patients with idiopathic or cryptogenic epilepsy.
In the study of Tan et al.,47 in which an association between
ABCB1_3435C>T polymorphism and drug-resistance of epilepsy
was not found, the TT genotype was more frequent in a subgroup
of patientswith temporal lobe epilepsy andhippocampal sclerosis
compared to those without it. Because temporal lobe epilepsy
with hippocampal sclerosis is usually more drug-resistant than
that without it, the authors suspected that this association was a
false positive. In another study performed in Caucasian patients
with temporal lobe epilepsy treated with multiple AEDs, a
signiﬁcant association of ABCB1_3435C>T, 2677G>T, and
1236C>T haplotype and drug-resistance was observed.43 How-
ever, in a recent study in Turkish patients, a signiﬁcant association
between ABCB1_3435C>T polymorphism and drug-resistance
was not found in a subgroup of patients with hippocampal
sclerosis.52 In a recent study in Korean patients with partial
epilepsy an association of drug-resistance with ABCB1, ABCG2,
and ABCC2 polymorphisms was not found, but stratiﬁcation into
idiopathic, cryptogenic and symptomatic subgroups was not
carried out.55
With respect to idiopathic epilepsies, in one study carried out in
patients with idiopathic generalized epilepsy with tonic–clonic
seizures treated with phenobarbital monotherapy, the
ABCB1_3435CC genotype was associated with signiﬁcantly lower
phenobarbital levels in cerebrospinal ﬂuid, signiﬁcantly lower CSF/
plasma ratio and signiﬁcantly higher seizure frequency than the CT
or the TT genotype.58 Our results do not agree with this study
because we have found an opposite tendency in the subgroup of
idiopathic epilepsies, but our results were not signiﬁcant.
Our results suggest that data obtained in children show an
opposite tendency with respect to adolescent-adults and those
obtained in patients with idiopathic epilepsies show an opposite
tendency with respect to symptomatic epilepsies. These opposite
results may have important consequencesmasking the association
between ABCB1 polymorphisms and drug-resistance when
patients are analyzed as a whole. However, we have not found a
plausible explanation for this opposite tendency. Tan et al.47
attributed the surprising overrepresentation of the ABCB1_3435TT
genotype in the subgroup of patients with temporal lobe epilepsy
and hippocampal sclerosis to a false positive. Ufer et al.33
attributed the surprising overrepresentation of ABCC2-24T variant
in drug-resistant children-adolescent patient to a compensatory
up-regulation of ABCB1. The surprising overrepresentation of
ABCB1_3435TT genotype in drug-resistant patients was found bySeo et al.30 in drug-resistant patients taking carbamazepine. We
cannot afﬁrm if this surprising opposite tendency found in children
and in idiopathic epilepsies is a chance, it is due to differences in
the antiepileptic drugs used or is due to compensatory mechan-
isms, but it can explain the differences in the association between
ABCB1 polymorphisms and drug-resistance of epilepsy found
between studies. Furthermore, this association could be unmasked
if patients are stratiﬁed by patient age or aetiology of epilepsy.
Nevertheless, the number of children and patients with idiopathic
epilepsies in our study is small and therefore, the insigniﬁcant
opposite tendency observed in our study should be conﬁrmed in a
larger and more speciﬁc study.
5. Conclusions
In our study, carried out on children and adolescent-adults with
multiple types of epilepsy and treated with multiple types of AEDs
we did not ﬁnd a signiﬁcant association between some SNPs
related with metabolism of AEDs (CYP2C9, CYP2C19, and UGT),
AEDs transport (ABCB1) and one of the main AED targets (SCN1A),
either in a crude analysis or adjusting by several clinical factors
associated with drug-resistance of epilepsy.
However, when patients were stratiﬁed by patient age or
aetiology of epilepsy a signiﬁcant association was found between
ABCB1 polymorphisms and drug-resistance. In the subgroup of
adults, those with the ABCB1_3435TT or 2677TT genotypes had a
lower risk of drug-resistance than those with the CC or the GG
genotypes, respectively. Furthermore, in the subgroup of patients
with symptomatic epilepsies, those with the ABCB1_3435CT or TT
genotypes had a lower risk of drug-resistance than those with the
CC genotype. An opposite, yet insigniﬁcant tendency was found in
children and in idiopathic epilepsies. Differences between children
and adults and between idiopathic and symptomatic epilepsies
could be attributed to the more frequent use of phenytoin and
phenobarbital (P-glycoprotein substrates) in adults and symptom-
atic epilepsies and themore frequent use of valproate (which is not
substrate of P-glycoprotein) in children and idiopathic epilepsies.
Our results could explain differences between the association or
lack of association between ABCB1 polymorphisms and epilepsy
drug-resistance found in different studies due to differences in the
percentage of children-adults and/or the percentage of idiopathic–
cryptogenic–symptomatic epilepsies in each study.
Although the stratiﬁcation by patient age and aetiology of
epilepsy was deﬁned pre-analysis, the small number of subjects do
not allow us to rule out that this may be a false positive association
due to chance. However, the high statistical signiﬁcance and the
biologic plausibility of the result (the TT genotypic association
conﬁrming the a priori hypothesis) lead us to suspect that there
may well be a true-positive association. Nevertheless, we consider
that a large study of replication is needed to conﬁrm our results
and distinguish a true association from a false positive.
Furthermore, we consider that the best way to investigate the
association between polymorphisms and drug-resistance should
be in patients suffering the same type of epilepsy and/or in those
treated with the same AEDs.
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